Scaling up a bioprocess from lab to production fundamentally alters physical properties like oxygen transfer (KLA). This change in physics, not necessarily a procedural mistake, is often the root cause of failure at scale, leading to different cell growth and product quality.

Altering the cell culture media after a master cell bank (MCB) has been created is a high-risk decision. It forces cells to adapt during the seed train of every GMP run, introducing unpredictable, stochastic scenarios where cell behavior can vary from batch to batch, compromising process robustness and consistency.

Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

The most common failure in automation is focusing on the robot or software. True success is determined by deeply understanding and codifying the entire process, including its environment and inherent variabilities. Getting the requirements right is the core challenge; the technology itself is secondary.

Contrary to the belief of those outside manufacturing, establishing a bioprocess is not a one-time task. The inherent unpredictability of biology means things will inevitably go wrong even in the most controlled environments, making it a continuous and difficult challenge.

For live cell therapies, the manufacturing process fundamentally shapes the biological product. Teams often rush to scale production, focusing on yield and cost. Instead, they should first fully understand how the process impacts cell potency and function to avoid effectively scaling the wrong biology.

A process that seems simple in a development lab is often not viable in a strict GMP manufacturing environment. To create truly manufacturable therapies, process development scientists need direct, hands-on exposure to GMP constraints and workflows to avoid significant rework and delays.

The trade-off between speed and process robustness is a false dichotomy. The key is to design a robust process that includes predefined and validated "pause steps." These holding points allow for flexibility to handle unforeseen issues like mechanical failures without compromising the entire batch, thus enabling both speed and quality.

To manage the unreliability of animal-derived raw materials, some companies run a complete pilot process alongside GMP production solely for pre-testing incoming lots. This extreme workaround highlights the immense hidden operational costs and inefficiencies that are accepted when process inputs are not fully defined.